These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7907441)

  • 1. [Methodology of clinical trials on basic treatments of osteoarthritis].
    Avouac B; Dropsy R
    Therapie; 1993; 48(4):315-9. PubMed ID: 7907441
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical assessment of osteoarthritis in clinical trials.
    Dougados M
    Curr Opin Rheumatol; 1995 Mar; 7(2):87-91. PubMed ID: 7766500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and conduct of clinical trials in osteoarthritis: preliminary recommendations from a task force of the Osteoarthritis Research Society.
    Hochberg MC; Altman RD; Brandt KD; Moskowitz RW
    J Rheumatol; 1997 Apr; 24(4):792-4. PubMed ID: 9101520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoarthritis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials.
    Bellamy N; Carette S; Ford PM; Kean WF; le Riche NG; Lussier A; Wells GA; Campbell J
    J Rheumatol; 1992 Mar; 19(3):444-50. PubMed ID: 1578461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials--results of a consensus development (Delphi) exercise.
    Bellamy N; Carette S; Ford PM; Kean WF; le Riche NG; Lussier A; Wells GA; Campbell J
    J Rheumatol; 1992 Mar; 19(3):451-7. PubMed ID: 1578462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Definitions and clinical experimentation of anti-osteoarthritis agents/chondro-protectors. Survey among private rheumatologists].
    Maheu E; Dropsy R
    Rev Rhum Mal Osteoartic; 1990 Oct; 57(9 ( Pt 2)):44S-50S. PubMed ID: 2080415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Objectives to be assigned to the various proposed treatments (NSAID, analgesics, preventive or curative fundamental treatments). Which type of patients for which type of clinical trials].
    Menkès CJ; Bardin T; Danglas P
    Rev Rhum Mal Osteoartic; 1990 Oct; 57(9 ( Pt 2)):22S-24S. PubMed ID: 2080412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reflections on the methodology for evaluating treatments of osteoarthritis].
    Bouvenot G
    Rev Rhum Ed Fr; 1994 Feb; 61(2):81-4. PubMed ID: 7920506
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development.
    Bellamy N
    Osteoarthritis Cartilage; 1999 Jul; 7(4):424-6. PubMed ID: 10419788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical evaluation of osteoarthritis in the elderly.
    Bellamy N
    Clin Rheum Dis; 1986 Apr; 12(1):131-53. PubMed ID: 3522082
    [No Abstract]   [Full Text] [Related]  

  • 11. MRI for development of disease-modifying osteoarthritis drugs.
    Burstein D
    NMR Biomed; 2006 Oct; 19(6):669-80. PubMed ID: 16986116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comprehensive osteoarthritis test: a simple index for measurement of treatment effects in clinical trials.
    Brooks LO; Rolfe MI; Cheras PA; Myers SP
    J Rheumatol; 2004 Jun; 31(6):1180-6. PubMed ID: 15170933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feprazone in osteoarthritis: comparison of twice and 3-times daily dosage regimens.
    Laurent MR; Berry D; Grahame R
    Pharmatherapeutica; 1983; 3(6):393-7. PubMed ID: 6353430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to evaluate the long-term course of osteoarthritis. Tests for trials of fundamental treatments (spine excluded)].
    Lequesne M; Dougados M; Abiteboul M; Bontoux D; Bouvenot G; Chicheportiche V; Dreiser RL; Dropsy R; Maheu E; Mazières B
    Rev Rhum Mal Osteoartic; 1990 Oct; 57(9 ( Pt 2)):24S-31S. PubMed ID: 2080413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoarthritis antirheumatic drug trials. I. Effects of standardization procedures on observer dependent outcome measures.
    Bellamy N; Carette S; Ford PM; Kean WF; le Riche NG; Lussier A; Wells GA; Campbell J
    J Rheumatol; 1992 Mar; 19(3):436-43. PubMed ID: 1578460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to OARSI FDA initiative OAC special edition.
    Abramson SB; Berenbaum F; Hochberg MC; Moskowitz RW
    Osteoarthritis Cartilage; 2011 May; 19(5):475-7. PubMed ID: 21396473
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucosamine for osteoarthritis.
    Med Lett Drugs Ther; 1997 Sep; 39(1010):91-2. PubMed ID: 9323961
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteoarthritis: symptoms, signs and source of pain.
    Kean WF; Kean R; Buchanan WW
    Inflammopharmacology; 2004; 12(1):3-31. PubMed ID: 15035776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodology of clinical trials in hand osteoarthritis. Issues and proposals.
    Maheu E; Dreiser RL; Lequesne M
    Rev Rhum Engl Ed; 1995 Jun; 62(6 Suppl 1):55S-62S. PubMed ID: 7583183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial of tramadol/acetaminophen tablets for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug.
    Ellman MH; Curran J
    J Rheumatol; 2005 Mar; 32(3):568; author reply 568-9. PubMed ID: 15742426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.